AB Science Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

AB Science yıllık ortalama 15.5% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.1% annual. Gelirler azalıyor .

Anahtar bilgiler

15.5%

Kazanç büyüme oranı

21.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	7.3%
Gelir büyüme oranı	-12.7%
Özkaynak getirisi	n/a
Net Marj	-558.5%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

AB Science nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:A8D Gelir, gider ve kazançlar (EUR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	1	-6	3	6
31 Mar 24	1	-9	3	8
31 Dec 23	1	-12	4	10
30 Sep 23	1	-14	3	11
30 Jun 23	1	-17	3	12
31 Mar 23	1	-15	3	13
31 Dec 22	1	-14	4	13
30 Sep 22	1	-15	4	14
30 Jun 22	1	-17	4	14
31 Mar 22	2	-16	4	13
31 Dec 21	2	-14	4	11
30 Sep 21	2	-13	4	12
30 Jun 21	2	-11	3	12
31 Mar 21	2	-13	3	12
31 Dec 20	2	-15	3	13
30 Sep 20	2	-16	3	12
30 Jun 20	2	-18	3	12
31 Mar 20	2	-20	3	14
31 Dec 19	2	-22	3	16
30 Sep 19	2	-25	3	19
30 Jun 19	2	-28	3	23
31 Mar 19	2	-27	3	25
31 Dec 18	2	-26	3	27
30 Sep 18	2	-25	3	27
30 Jun 18	2	-25	3	27
31 Mar 18	2	-26	3	27
31 Dec 17	2	-27	3	27
30 Sep 17	2	-27	3	26
30 Jun 17	2	-26	3	26
31 Mar 17	2	-27	3	27
31 Dec 16	2	-28	3	28
30 Sep 16	2	-28	4	27
30 Jun 16	2	-28	4	27
31 Mar 16	2	-28	4	25
31 Dec 15	2	-27	4	24
30 Sep 15	2	-24	4	21
30 Jun 15	2	-22	4	19
31 Mar 15	2	-19	4	16
31 Dec 14	2	-16	4	13
30 Sep 14	2	-16	4	13
30 Jun 14	2	-15	3	13
31 Mar 14	2	-15	3	12
31 Dec 13	2	-15	3	12

Kaliteli Kazançlar: A8D şu anda kârlı değil.

Büyüyen Kar Marjı: A8D şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: A8D kârlı değildir, ancak son 5 yılda zararlarını yılda 15.5% oranında azaltmıştır.

Büyüme Hızlandırma: A8D 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: A8D kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 28.7% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: A8D 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

AB Science Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: €0.09 loss per share (vs €0.22 loss in 1H 2023)

Full year 2023 earnings released

AB Science S.A. to Report First Half, 2024 Results on Sep 30, 2024

First half 2023 earnings released: €0.22 loss per share (vs €0.15 loss in 1H 2022)

Full year 2022 earnings released: €0.29 loss per share (vs €0.30 loss in FY 2021)

AB Science S.A. to Report Fiscal Year 2022 Results on Apr 28, 2023

Recent updates

AB Science Receives Notice of Allowance for European Patent Covering Masitinib Until 2040 in the Treatment of Sickle Cell Disease

First half 2024 earnings released: €0.09 loss per share (vs €0.22 loss in 1H 2023)

AB Science Announces Positive Results of Its Phase 2 Study Evaluating Masitinib in Covid-19

Insufficient new directors

New minor risk - Market cap size

AB Science S.A., Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released

New minor risk - Financial data availability

AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS

AB Science S.A. to Report First Half, 2024 Results on Sep 30, 2024

AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis

First half 2023 earnings released: €0.22 loss per share (vs €0.15 loss in 1H 2022)

New minor risk - Financial data availability

New minor risk - Financial data availability

New minor risk - Shareholder dilution

AB Science S.A. Receives Notice of Allowance for European Patent Covering Masitinib in the Treatment of Metastatic Castrate Refractory Prostate Cancer (mCRPC)

Full year 2022 earnings released: €0.29 loss per share (vs €0.30 loss in FY 2021)

AB Science S.A. to Report Fiscal Year 2022 Results on Apr 28, 2023

AB Science S.A. Receives Approval from the U.S. Food and Drug Administration (FDA) to Initiate the Confirmatory Phase 3 Study with Masitinib in the Treatment of Progressive Multiple Sclerosis

AB Science S.A. announced that it expects to receive €15 million in funding from European Investment Bank, Investment Arm

AB Science SA Receives Notice of Deficiency from Health Canada for Masitinib in Treatment of Amyotrophic Lateral Sclerosis

AB Science SA Receives U.S. Food and Drug Administration Authorization to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer’s Disease

AB Science Sa Receives First Agencies Authorizations to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer's Disease

First half 2022 earnings released: EPS: €0 (vs €0.099 loss in 1H 2021)

AB Science SA Announces Positive Recommendation of Data and Safety Monitoring Board to Continue Phase 2 Study Evaluating Antiviral Activity of Masitinib in Covid-19

AB Science Announces That It Has Filed an Application for Conditional Marketing Authorization to EMA for Masitinib in the Treatment of ALS

AB Science SA Announces Publication of Results from its Positive Study of Masitinib in Severe Asthma Uncontrolled by Oral Corticosteroids in the Peer-Reviewed Journal of Asthma and Allergy

AB Science Announces Changes in the Board of Directors

AB Science S.A. Announces Publication of Results from Its Positive Pivotal Phase 3 Trial of Masitinib in Progressive Forms of Multiple Sclerosis in the Peer-Reviewed Journal Neurology® Neuroimmunology & Neuroinflammation

AB Science SA Announces Health Canada Has Granted Authorization to File New Drug Submission for Masitinib in the Treatment of ALS Under the Notice of Compliance with Conditions (NOC/c) Policy

AB Science SA Grants Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the Swedish Medical Products Agency

AB Science SA Receives Authorization to Initiate Phase II Study in Patients with Severe Mast Cell Activation Syndrome by the French Health Authority (ANSM)

AB Science Announces That It Has Been Granted Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the French Health Authority (ANSM)

AB Science S.A. Announces Dosing of First Patient in Phase 2 Trial of Masitinib’s Antiviral Activity Against the SARS-CoV-2 (Covid-19) Virus

AB Science Receives FDA Authorization to Initiate Phase 1/Ii Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia

First half 2021 earnings released: €0.099 loss per share (vs €0.23 loss in 1H 2020)

AB Science SA Receives Regulatory Authorization to Commence A Second Phase 2 Covid-19 Study

AB Science S.A. Receives Health Canada Approval Letter to Commence Phase I/II Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia (AML)

AB Science S.A. Receives Authorization to Resume Patient Enrollment in the Phase 2 Masitinib Study of Covid-19

AB Science S.A. Receives New Authorizations to Resume Patient Enrollment in Its Phase 3 Studies of Masitinib

AB Science Announces Results from Masitinib Study Ab12003 in Prostate Cancer Have Been Presented At the 2021 American Urological Association

AB Science SA Announces That It Has Received Second Authorization to Resume Patient Enrollment, in the Phase 3 Study of Masitinib in Mastocytosis

AB Science Announces Receives the First Authorization to Resume Patient Enrollment in the Confirmatory Phase 3 Study of Masitinib (AB19001) in ALS

AB Science Announces the Validation of Its Risk Management Plan by the French National Agency (ANSM) in Order to Restart Patient Enrollment in France

AB Science SA Announces Results from Masitinib Study AB12005 in Pancreatic Cancer Have Been Presented At the 2021 Asco Annual Meeting

AB Science SA Announces Update of Masitinib

AB Science SA Communicates Results from Phase 3 Study Evaluating Masitinib in Prostate Cancer

AB Science Sa Announces Results from Masitinib Study AB12005 in Pancreatic Cancer, Have Been Selected for Presentation at the Upcoming Asco Annual Meeting

Full year 2020 earnings released

AB Science Sa Announces Identification of Two Tissue Biomarkers That Could Potentially Serve as Predictive Biomarkers of Response for Masitinib Treatment

AB Science Announces a New Independent Publication Confirms That Masitinib Has Anti-Vital Activity Against the SARS-CoV-2 Virus in Vitro and Is A Promising Candidate for Treating COVID-19

AB Science S.A. has completed a Follow-on Equity Offering in the amount of €10.50001 million.

AB Science Issues A Corrective Press Release Regarding Adverse Events Information from Study AB09004 Reported on December 16, 2020

AB Science Announces That Phase 2B/3 Study Evaluating Oral in Alzheimer’S Disease Met Its Primary Endpoint

New 90-day high: €14.44

AB Science S.A. Announces That Confirmatory Phase 3 Study AB12005 with Masitinib in First Line Pancreatic Cancer with Pain Was Successful

AB Science S.A. Announces Results from masitinib Study AB07015 in Severe Asthma Have Been Selected for Presentation At an ATS Symposium Held on October 16, 2020

First half earnings released

AB Science SA Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Large Multiple Sclerosis Research Conference

New 90-day high - €13.28

New 90-day high - €10.12

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin